

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1681)**

## **NOTICE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of Consun Pharmaceutical Group Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on Tuesday, 19 August 2025 for the following purposes:

1. To consider and approve the unaudited consolidated interim results of the Company and its subsidiaries for the six months ended 30 June 2025 (the “**Interim Results**”);
2. To consider and approve the announcement of the Interim Results to be published in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited;
3. To consider the payment of an interim dividend, if any; and
4. To consider and approve other matters, if any.

By order of the Board  
**Consun Pharmaceutical Group Limited**  
**An Meng**  
*Chairman*

Hong Kong, 5 August 2025

*As at the date of this announcement, the Board comprises Mr. An Meng, Professor Zhu Quan and Mr. Young Yuk Chuen David as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi, Professor Li Yikai, Mr. Li Zhuoguang and Mr. Duan Weiwu as independent non-executive Directors.*